Navneet S. Majhail, Elizabeth A. Murphy, Nancy A

Slides:

Advertisements

Similar presentations

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Advertisements

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Treatment of Severe Hemorrhagic Cystitis after Allogeneic Stem Cell Transplantation with Palifermin, a Recombinant Human Keratinocyte Growth Factor Akos.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplantation Clinical Trials Ellen M. Denzen, Martha E. Burton Santibáñez, Heather Moore,

How to Treat MDS without Stem Cell Transplantation

A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors Navneet S. Majhail, Hillard M. Lazarus, Linda.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s.

Allogeneic Stem Cell Transplantation in Myelofibrosis

National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants Robert A. Bray, Carolyn K. Hurley, Naynesh.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Access to Hematopoietic Cell Transplantation in the United States

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Patient and Provider Preferences for Survivorship Care Plans for Allogeneic Hematopoietic Cell Transplantation (HCT) Survivors: A Qualitative Study Ellen.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High- Risk Allogeneic Transplant Recipients Sheila Serafino, Navneet S. Majhail,

Hematopoietic Cell Transplantation in 2020: Summary of Year 2 Recommendations of the National Marrow Donor Program's System Capacity Initiative Ellen.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report Shahrukh K. Hashmi, Christopher.

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative.

B Cells and Transplantation: An Educational Resource

On Modeling Human Leukocyte Antigen–Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients James L. Gajewski, Mark.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant.

High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry Kelly Buck, Kim Wadsworth, Michelle Setterholm, Martin.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery Navneet S. Majhail, Lih-Wen Mau,

What is quality in a transplant program?

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation Jennifer Beswick, Elizabeth.

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

The New Apheresis and Blood and Marrow Transplantation–Related Current Procedural Terminology Codes for Payment of Apheresis and Blood and Marrow Transplantation.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence Fausto R. Loberiza, Stephanie.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Presentation transcript:

Allogeneic Transplant Physician and Center Capacity in the United States Navneet S. Majhail, Elizabeth A. Murphy, Nancy A. Omondi, Pam Robinett, James L. Gajewski, C.Fred LeMaistre, Dennis Confer, J. Douglas Rizzo Biology of Blood and Marrow Transplantation Volume 17, Issue 7, Pages 956-961 (July 2011) DOI: 10.1016/j.bbmt.2011.03.008 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Allogeneic HCT activity among U.S. centers in the NMDP network between 2005 and 2009. Growth in allogeneic HCT volume was primarily attributed to an increase in NMDP-facilitated unrelated donor transplants in centers that were members of the network since at least 2005. Biology of Blood and Marrow Transplantation 2011 17, 956-961DOI: (10.1016/j.bbmt.2011.03.008) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Contribution of existing and new NMDP network centers on growth in allogeneic transplant activity, transplant beds, and physician FTEs from 2005 to 2009. Biology of Blood and Marrow Transplantation 2011 17, 956-961DOI: (10.1016/j.bbmt.2011.03.008) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Scatter plot of number of allogeneic HCT versus number of transplant beds among U.S. centers in the NMDP network in 2009. Biology of Blood and Marrow Transplantation 2011 17, 956-961DOI: (10.1016/j.bbmt.2011.03.008) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Center size and (A) median number of allogeneic HCT/center, (B) median number of transplant physician FTEs/center, (C) median number of allogeneic HCT/bed, and (D) median number of allogeneic HCT/physician FTE. This analysis was limited to 110 centers that participated in the NMDP network for all 5 years. Biology of Blood and Marrow Transplantation 2011 17, 956-961DOI: (10.1016/j.bbmt.2011.03.008) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions